Szerző: " Kaufman B."

Miles D.; Ciruelos E.; Schneeweiss A.; Puglisi F.; Peretz-Yablonski T.; Campone M.; Bondarenko I.; Nowecki Z.; Errihani H.; Paluch-Shimon S.; Wardley A.; Merot J.-L.; Trask P.; du Toit Y.; Pena-Murillo C.; Revelant V.; Klingbiel D.; Bachelot T.; Bouzid K.; Desmoulins I.; Coudert B.; Glogowska I.; Ciruelos Gil E.; Dalenc F.; Ricci F.; Dieras V.; Kaufman B.; Ferreira A.; Mano M.; Kalofonos H.; Hitre Erika; Láng István; Horváth Zsolt; Bodoky György; Kahán Zsuzsanna; Kollaborációs szervezet: PERUSE investigators; et al.: Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
ANNALS OF ONCOLOGY, 32 (10). pp. 1245-1255. ISSN 0923-7534 (2021)

Brodowicz Thomas; Láng István; Kahán Zsuzsanna; Greil R.; Beslija Semir; Stemmer Salomon M.; Kaufman B.; Petruzelka L.; Eniu A.; Anghel Rodica; Koynov K.; Vrbanec Damir; Pieńkowski Tadeusz; Melichar B.; Spanik S.; Ahlers S.; Messinger Diethelm; Inbar Moshe J.; Zielinski Christoph: Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses.
BRITISH JOURNAL OF CANCER, 111 (11). pp. 2051-2057. ISSN 0007-0920 (2014)